Company intelligence / Profile preview
Vivesto AB
Swedenvivesto.com ↗
- Ownership
- Public · VIVE
- Development stage
- Phase 2
01
Overview
Vivesto has one approved product (Apealea/paclitaxel micellar) for ovarian cancer in Europe, and recently reported positive results for Cantrixil in an animal hematological cancer model on April 1, 2025. The company signed a deal with Kazia Therapeutics to acquire full Cantrixil rights on March 31, 2025.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
InceptuaKazia TherapeuticsBaxter Oncology GmbH
04
Financials
- Market cap
- $3.9M
- Total revenue
- $0
- Enterprise value
- $1.5M
Beyond the preview
Go deeper on Vivesto AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vivesto AB.